WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)

ENGLISH DEUTSCH
PDF Download back

 

Munich, Germany, 26 October 2016 – WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, entered into a research collaboration with Nordic Nanovector ASA, Oslo, Norway (Ticker: NANO), a biotech company focusing on the development and commercialization of novel targeted therapeutics in hematology and oncology. The collaboration aims at developing novel antibody drug conjugates (ADCs) to treat leukemias. Leukemias are orphan diseases with a significant unmet medical need, applicable indications representing a growing market worth over USD 5 billion by 2020[1] [2].

Professor Dr Andreas Pahl, Head of Research & Development and member of the Management Board of WILEX and Heidelberg Pharma, commented: “The project extends our ADC portfolio to additional hematological cancers. Nordic Nanovector has an established chemistry, manufacturing, and controls (CMC) process for their antibody which will speed up processes and reduce the development costs of the ADCs.”

Jostein Dahle, Nordic Nanovector’s Chief Scientific Officer, added: “We are pleased to further expand our R&D activities into the ADC area with Heidelberg Pharma. During the past year, we have made important steps to execute our strategy designed to build a pipeline of innovative antibody-radionuclide conjugates (ARCs) and ADCs that combine our expertise and platform with complementary technologies from expert partners.”


[1] http://www.thepharmaletter.com/article/acute-myeloid-leukemia-market-to-be-worth-1-67-billion-by- 2020

[2] Global Data, Opportunity Analyser: CLL, 2014

About WILEX and Heidelberg Pharma’s proprietary ATAC technology
WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company’s research and development work is conducted by its subsidiary, Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma is focused on developing an innovative ADC technology platform based on the compound Amanitin (ATAC technology) and also provides preclinical drug research and development services.

Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer and inflammatory diseases. ATACs are ADCs that are bound to highly potent amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combatting even quiescent tumor cells.

Heidelberg Pharma is working on several ATAC candidates with industry partners as well as on its own ATAC pipeline. The lead candidate HDP-101, a BCMA ATAC, has been selected for the preclinical and clinical development in multiple myeloma, the third most common hematologic cancer.

WILEX has diagnostic and therapeutic Phase III drug candidates, which are available for out-licensing. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.wilex.com and www.heidelberg-pharma.com.

About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in hematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumor-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com

This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Contact
WILEX AG

Sylvia Wimmer
Corporate Communications
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 18, 81675 Munich, Germany
IR/PR support
MC Services AG

Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
Email: katja.arnold[at]mc-services.eu
For Nordic Nanovector
IR enquiries:
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir[at]nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
Email: nordicnanovector[at]citigatedr.co.uk

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.

Seite gelesen: 803 | Heute: 3